Company Encyclopedia
View More
name
Veru
VERU.US
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc.
4.514 T
VERU.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking92/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-106.02%E
    • Profit Margin-193.71%E
    • Gross Margin0.00%E
  • Growth ScoreB
    • Revenue YoY337.24%A
    • Net Profit YoY12.55%C
    • Total Assets YoY-57.71%E
    • Net Assets YoY-59.21%E
  • Cash ScoreB
    • Cash Flow Margin-51.62%D
    • OCF YoY337.24%A
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreC
    • Gearing Ratio43.86%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Veru Inc. unveils pipeline targeting obesity and cardiometabolic disease with novel drug combinations

    Veru Inc. has unveiled a new drug pipeline targeting obesity and cardiometabolic disease, featuring novel combinations like Enobosarm and GLP-1 receptor agonists. The Phase 2 QUALITY Study is complete, with Phase 2b PLATEAU study starting in 2026. Veru is also advancing Sabizabulin for atherosclerosis treatment. The presentation highlights the growing use of GLP-1 therapies and associated challenges. This news was generated by AI and is for informational purposes only.

    Reuters·
    US
    VERU
    0.00%
    Reuters·
    US
    VERU
    0.00%

    Veru Announces Public Offering to Raise $23.4 Million

    Veru Inc. has announced a public offering of 8,400,000 shares, expected to raise approximately $23.4 million, primarily to fund the development of enobosarm and for general corporate purposes. The offering is set to close around October 31, 2025. Analysts rate VERU stock as a Hold with a $3.50 price target, while Spark's AI Analyst considers it Neutral due to weak financial performance and ongoing losses. Veru focuses on developing treatments for cardiometabolic and inflammatory diseases, with a current market cap of $51.3 million.

    Tip Ranks·
    US
    VERU
    0.00%
    Tip Ranks·
    US
    VERU
    0.00%

    Veru Dives on Public Float

    Veru Inc. (NASDAQ: VERU) shares fell 13.7% to $3.02 following the announcement of a public offering. The Miami-based biopharmaceutical company is offering 1.4 million shares of common stock, pre-funded warrants for 7 million shares, and Series A and B warrants for 8.4 million shares each, priced at $3.00 per share. The offering aims to raise approximately $25.2 million and is expected to close by October 31, 2025.

    Baystreet·
    US
    VERU
    0.00%
    Baystreet·
    US
    VERU
    0.00%

    BUZZ-Biopharma co Veru tumbles on planned stock-and-warrants offering

    Shares of biopharmaceutical company Verufell 20% to $2.79 in post-market trading following its announcement of a stock and warrants offering. The deal size remains undisclosed, and the proceeds will fund the development of enobosarm, aimed at combating muscle loss in overweight or obese patients. Veru has approximately 14.6 million shares outstanding and a market cap of about $50 million. The stock has seen a year-to-date loss of 46%.

    Reuters·
    US
    VERU
    0.00%
    Reuters·
    US
    VERU
    0.00%

    Veru shares are trading lower after the company announced a proposed public offering.

    benzinga_article·
    US
    VERU
    0.00%
    benzinga_article·
    US
    VERU
    0.00%
    © 2025 Longbridge｜Disclaimer